Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib

Biomedicine and Pharmacotherapy

Volumn 66, Issue 5, 2012, Pages 384-389

  Xu, Ruitong ^a   Shen, Hua ^a   Guo, Renhua ^a   Sun, Jing ^a   Gao, Wen ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

EGFR ER pathway; Fulvestrant; Gefitinib; NSCLC; T790M mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84864003093     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.02.004     Document Type: Article

References (45)

1. Statistics, Information, Department Labour and Welfare of Japan. Vital Statistics of Japan 2003 2003, Health and Welfare Statistics Association, Tokyo.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
3. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-2385.
4. Nicholson R.L., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer 2001, 37:S9-S15.
5. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
6. Uramoto H., Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. Br J Cancer 2007, 96:857-863.
7. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
8. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
9. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
10. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
11. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
12. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
13. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
14. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase Il trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
15. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
16. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
17. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
18. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005, 102:7665-7670.
19. Patel J.D., Bach P.B., Kris M.G. Lung cancer in US women. A contemporary epidemic. JAMA 2004, 291:1763-1768.
20. Cheng G., Weihua Z., Warner M., et al. Estrogen receptors ERα and ERß in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A 2004, 101:3739-3746.
21. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240:889-895.
22. Murdoch F.E., Gorski J. The role of ligand in estrogen receptor regulation of gene expression. Mol Cell Endocrinol 1991, 78:C103-C108.
23. McKenna N.J., O'Malley B.W. An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat Med 2000, 6:960-962.
24. Stabile L.P., Davis A.L., Gubish C.T., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and h and show biological responses to estrogen. Cancer Res 2002, 62:2141-2150.
25. Hershberger P.A., Vasquez A.C., Siegfried J.M. Lung cancer cells express estrogen receptor (ER) and coactivators and undergo changes in gene expression in response to ER ligands. Proc AACR 2004, 45:289.
26. Stabile L.P., Lyker J.S., Gubish C.T., et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65:1459-1470.
27. Márquez-Garbán D.C., Chen H.W., Fishbein M.C., et al. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007, 72:135-143.
28. Traynora AM, Schiller JHB, Stabile LP, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung cancer 2008:3119-28.
29. Beattie C.W., Hansen N.W., Thomas P.A. Steroid receptors in human lung cancer. Cancer Res 1985, 45:4206-4214.
30. Omoto Y., Kobayashi Y., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285:340-347.
31. Pietras R.J., Márquez D.C., et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70:372-381.
32. Niikawa H., Suzuki T., et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008, 14:4417-4426.
33. Mollerup S., Jorgensen K., et al. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37:153-159.
34. Ganti A.K., Sahmoun A.E., et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006, 24:59-63.
35. Weinberg O.K., Márquez-Garbán D.C., et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005, 65:11287-11291.
36. Mah V., Seligson B., et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007, 67:10484-10490.
37. Alì G., Donati V., Loggini B., et al. Different estrogen receptor p expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008, 39:1465-1473.
38. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12(21):6494-6501.
39. Daub H., Specht K., Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004, 3(12):1001-1010.
40. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
41. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
42. Sos M.L., Zander T., Thomas R.K., et al. Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. J Thorac Oncol 2008, 3(2):170-173.
43. Li D., Shimamura T., Ji H., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12:81-93.
44. Tsuyoshi S., Akihiro F., Junichi O., et al. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci 2009, 100:1526-1531.
45. Regales L., Gong Y., Shen R., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119:3000-3010.